FULC

FULC

USD

Fulcrum Therapeutics Inc. Common Stock

$8.370-0.460 (-5.210%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$8.830

高値

$9.020

安値

$8.300

出来高

0.37M

企業ファンダメンタルズ

時価総額

453.0M

業種

バイオテクノロジー

United States

取引統計

平均出来高

0.53M

取引所

NGM

通貨

USD

52週レンジ

安値 $2.315現在値 $8.370高値 $10.11

関連ニュース

GlobeNewswire

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be

もっと見る
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Analyst Upgrades

RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7

RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics with a Sector Perform and raises the price target from $5 to $7.

もっと見る
RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7
Analyst Upgrades

Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16

Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics with a Overweight and raises the price target from $12.5 to $16.

もっと見る
Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16
GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the

もっと見る
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
GlobeNewswire

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives

もっと見る
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET